EA036714B1 - Частичные агонисты инсулинового рецептора - Google Patents

Частичные агонисты инсулинового рецептора Download PDF

Info

Publication number
EA036714B1
EA036714B1 EA201791117A EA201791117A EA036714B1 EA 036714 B1 EA036714 B1 EA 036714B1 EA 201791117 A EA201791117 A EA 201791117A EA 201791117 A EA201791117 A EA 201791117A EA 036714 B1 EA036714 B1 EA 036714B1
Authority
EA
Eurasian Patent Office
Prior art keywords
insulin
linker
group
chain
moiety
Prior art date
Application number
EA201791117A
Other languages
English (en)
Russian (ru)
Other versions
EA201791117A1 (ru
Inventor
Суннянь Линь
Линь Янь
Пэй Хо
Дмитрий Писсарницки
Даньцин Фэн
Рави Наргунд
Юйпин Чжу
Ахмет Кекедж
Кристина Б. Мадсен-Дугган
Чжи-цай Ши
Чжицай У
Инцзюнь Му
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of EA201791117A1 publication Critical patent/EA201791117A1/ru
Publication of EA036714B1 publication Critical patent/EA036714B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA201791117A 2014-11-21 2015-11-19 Частичные агонисты инсулинового рецептора EA036714B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16
PCT/US2015/061445 WO2016081670A2 (en) 2014-11-21 2015-11-19 Insulin receptor partial agonists

Publications (2)

Publication Number Publication Date
EA201791117A1 EA201791117A1 (ru) 2017-11-30
EA036714B1 true EA036714B1 (ru) 2020-12-10

Family

ID=54838417

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791117A EA036714B1 (ru) 2014-11-21 2015-11-19 Частичные агонисты инсулинового рецептора

Country Status (27)

Country Link
US (4) US20170355743A1 (ja)
EP (4) EP3666792A3 (ja)
JP (5) JP6484337B2 (ja)
KR (2) KR102101136B1 (ja)
CN (2) CN112494656B (ja)
AR (1) AR102712A1 (ja)
AU (3) AU2015349890B2 (ja)
BR (2) BR122024000898A2 (ja)
CA (2) CA3014641C (ja)
CL (3) CL2017001288A1 (ja)
CO (1) CO2017004976A2 (ja)
CR (1) CR20170208A (ja)
DO (1) DOP2017000124A (ja)
EA (1) EA036714B1 (ja)
ES (1) ES2946247T3 (ja)
GT (1) GT201700104A (ja)
IL (1) IL252257A0 (ja)
MX (3) MX2017006651A (ja)
NI (1) NI201700060A (ja)
PE (1) PE20170957A1 (ja)
PH (1) PH12017500935A1 (ja)
SG (4) SG10201809427SA (ja)
SV (1) SV2017005445A (ja)
TN (1) TN2017000178A1 (ja)
TW (1) TW201625673A (ja)
WO (1) WO2016081670A2 (ja)
ZA (1) ZA201703238B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63190B1 (sr) 2014-08-04 2022-06-30 Nuevolution As Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti
US20170355743A1 (en) * 2014-11-21 2017-12-14 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
US10953076B2 (en) 2016-05-24 2021-03-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and GLP-1 analogues
WO2017205309A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
WO2018077851A1 (en) * 2016-10-24 2018-05-03 Novo Nordisk A/S Bioassay for insulin formulations
MA49896A (fr) 2017-08-17 2020-06-24 Novo Nordisk As Nouveaux analogues d'insuline acylés et leurs utilisations
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
WO2022046747A1 (en) * 2020-08-26 2022-03-03 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
JP2023540746A (ja) * 2020-09-03 2023-09-26 ダイン セラピューティクス，インコーポレーテッド タンパク質－オリゴヌクレオチド複合体の調製方法
EP4210729A2 (en) * 2020-09-09 2023-07-19 Merck Sharp & Dohme LLC Insulin receptor partial agonists
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050456A2 (de) * 1999-02-24 2000-08-31 Aventis Pharma Deutschland Gmbh Kovalent verbrückte insulindimere
WO2013063572A1 (en) * 2011-10-27 2013-05-02 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
WO2014052451A2 (en) * 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
AU4672699A (en) * 1998-06-08 1999-12-30 Theravance, Inc. Novel sodium channel drugs and uses
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
US7375234B2 (en) 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
WO2006045710A2 (en) 2004-10-27 2006-05-04 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104737A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
EP2054437A2 (en) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
RU2010147076A (ru) 2008-04-22 2012-05-27 Кейз Вестерн Ризев Юнивесити (Us) Аналоги инсулина специфичные к изоформам
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
KR101820024B1 (ko) * 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CA2747490C (en) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
US20140315797A1 (en) * 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
US20160067212A1 (en) 2013-03-15 2016-03-10 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
CN105792852B (zh) * 2013-10-04 2019-12-10 默沙东公司 葡萄糖响应性的胰岛素缀合物
EP3068443B1 (en) * 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Residualizing linkers and uses thereof
BR112016016578A2 (pt) 2014-01-20 2017-10-03 Hanmi Pharm Ind Co Ltd Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
US20170355743A1 (en) 2014-11-21 2017-12-14 Merck Sharp & Dohme Corp. Insulin receptor partial agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050456A2 (de) * 1999-02-24 2000-08-31 Aventis Pharma Deutschland Gmbh Kovalent verbrückte insulindimere
WO2013063572A1 (en) * 2011-10-27 2013-05-02 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
WO2014052451A2 (en) * 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEPPE, C. ET AL.: "Structure-activity relationship of covalently dimerized insulin derivatives: correlation of partial agonist efficacy with cross-linkage at lysine B29", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, DE, vol. 350, no. 2, 1 August 1994 (1994-08-01), DE, pages 213 - 217, XP000925874, ISSN: 0028-1298 *
JOHN Harold et al.: N-Terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. European Journal of Medical Research, 2008, v. 13, pp. 73-78, реферат, с. 75-77 *
JOHN P. MAYER, FAMING ZHANG, RICHARD D. DIMARCHI: "Insulin Structure and Function", BIOPOLYMERS, JOHN WILEY & SONS, INC., US, vol. 88, no. 5, 1 January 2007 (2007-01-01), US, pages 687 - 713, XP008152505, ISSN: 0006-3525, DOI: 10.1002/bip.20734 *
SCHUETTLER, A. & BRANDENBURG, D.: "Preparation and Properties of Covalently Linked Insulin Dimers", HOPPE-SEYLER'S ZEITSCHRIFT FUER PHYSIOLOGISCHE CHEMIE., WALTER DE GRUYTER, BERLIN, DE, vol. 363, no. 3, 1 March 1982 (1982-03-01), DE, pages 317 - 330, XP000925886, ISSN: 0018-4888 *

Also Published As

Publication number Publication date
JP2019014734A (ja) 2019-01-31
EA201791117A1 (ru) 2017-11-30
CR20170208A (es) 2017-07-17
WO2016081670A2 (en) 2016-05-26
AU2018211207A1 (en) 2018-08-16
AU2018211208A1 (en) 2018-08-16
TN2017000178A1 (en) 2018-10-19
CA3014641A1 (en) 2016-05-26
US20180291078A1 (en) 2018-10-11
BR122024000903A2 (pt) 2024-02-27
IL252257A0 (en) 2017-07-31
CN112494656B (zh) 2024-01-30
SV2017005445A (es) 2018-04-04
EP3666792A2 (en) 2020-06-17
CL2019001143A1 (es) 2019-07-19
SG10201809457YA (en) 2018-11-29
BR112017010481A8 (pt) 2023-04-11
AU2018211208B2 (en) 2020-09-10
AU2015349890B2 (en) 2018-08-30
KR20170084300A (ko) 2017-07-19
ES2946247T3 (es) 2023-07-14
WO2016081670A3 (en) 2016-08-04
MX2017006651A (es) 2017-08-21
MX2020014120A (es) 2021-03-25
SG10201809428UA (en) 2018-11-29
JP2019014735A (ja) 2019-01-31
KR20190069622A (ko) 2019-06-19
CA2966765A1 (en) 2016-05-26
KR102101136B1 (ko) 2020-04-14
CA2966765C (en) 2020-04-14
EP3660041B1 (en) 2023-04-19
CA3014641C (en) 2020-08-18
JP2018501203A (ja) 2018-01-18
EP3666792A3 (en) 2020-07-29
BR112017010481A2 (pt) 2018-04-03
EP3660041A1 (en) 2020-06-03
CN108064173B (zh) 2021-05-18
AR102712A1 (es) 2017-03-22
EP3660040A2 (en) 2020-06-03
US10800827B2 (en) 2020-10-13
US10183981B2 (en) 2019-01-22
JP6703068B2 (ja) 2020-06-03
SG10201809427SA (en) 2018-11-29
EP3660040A3 (en) 2020-07-29
US20170107268A1 (en) 2017-04-20
ZA201703238B (en) 2018-05-30
PE20170957A1 (es) 2017-07-13
MX2020014121A (es) 2021-03-25
US10017556B2 (en) 2018-07-10
JP6484337B2 (ja) 2019-03-13
AU2018211207B2 (en) 2020-04-09
PH12017500935A1 (en) 2017-11-27
TW201625673A (zh) 2016-07-16
DOP2017000124A (es) 2017-08-15
SG11201704064TA (en) 2017-06-29
JP6931033B2 (ja) 2021-09-01
NI201700060A (es) 2017-07-18
US20190092833A1 (en) 2019-03-28
EP3221343B1 (en) 2020-09-16
JP6943825B2 (ja) 2021-10-06
JP2020097572A (ja) 2020-06-25
GT201700104A (es) 2018-11-27
JP2019011357A (ja) 2019-01-24
CN112494656A (zh) 2021-03-16
BR122024000898A2 (pt) 2024-02-27
EP3221343A2 (en) 2017-09-27
CL2019001144A1 (es) 2019-07-19
US20170355743A1 (en) 2017-12-14
CL2017001288A1 (es) 2017-12-15
CO2017004976A2 (es) 2017-10-10
KR102049647B1 (ko) 2019-11-29
CN108064173A (zh) 2018-05-22
AU2015349890A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
US10800827B2 (en) Insulin receptor partial agonists
US20190142906A1 (en) Insulin receptor partial agonists and glp-1 analogues
US10689430B2 (en) Insulin receptor partial agonists
EA041034B1 (ru) Частичные агонисты инсулинового рецептора
WO2022055877A2 (en) Insulin receptor partial agonists
BR112017010481B1 (pt) Composto útil como agonista parcial de receptor de insulina, composição, e, uso de uma composição